Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

China flag China · Delayed Price · Currency is CNY
42.32
-1.00 (-2.31%)
Apr 30, 2026, 2:55 PM CST
121.80%
Market Cap 5.20B
Revenue (ttm) 688.74M
Net Income (ttm) 44.38M
Shares Out 120.00M
EPS (ttm) 0.37
PE Ratio 117.11
Forward PE n/a
Dividend 0.10 (0.24%)
Ex-Dividend Date n/a
Volume 3,932,200
Average Volume 5,563,730
Open 41.54
Previous Close 43.32
Day's Range 41.54 - 43.32
52-Week Range 18.97 - 81.88
Beta 0.29
RSI 50.36
Earnings Date Apr 25, 2026

About SHE:300584

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; ... [Read more]

Sector Healthcare
Founded 2003
Employees 548
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300584
Full Company Profile

Financial Performance

In 2025, SHE:300584's revenue was 671.05 million, an increase of 33.05% compared to the previous year's 504.36 million. Earnings were 42.06 million, an increase of 4.58%.

Financial Statements

News

There is no news available yet.